IW 9179

Drug Profile

IW 9179

Alternative Names: IW-9179

Latest Information Update: 12 Apr 2016

Price : $50

At a glance

  • Originator Ironwood Pharmaceuticals
  • Class Antiulcers; Gastrokinetics; Peptides
  • Mechanism of Action Guanylate cyclase C agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dyspepsia
  • Discontinued Diabetic gastroparesis

Most Recent Events

  • 05 Apr 2016 Discontinued - Phase-II for Diabetic gastroparesis in USA (PO)
  • 05 Apr 2016 Top-line adverse events data from a phase IIa trial in Diabetic gastroparesis released by Ironwood Pharmaceuticals
  • 17 Aug 2015 Phase-II development for Functional dyspepsia is ongoing in Belgium and Netherlands
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top